Advertisement
Advertisement
July 8, 2024
Microbot’s Liberty System Pivotal Trial Commences Enrollment
July 8, 2024—Microbot Medical Inc. announced the completion of the first procedure in a patient using its Liberty endovascular robotic surgical system as part of the company’s pivotal clinical trial for the device.
According to Microbot, the trial is being conducted under an FDA investigational device exemption for Liberty. The company expects the trial results will support the future submission of Liberty to the FDA and its subsequent commercialization.
The procedure was performed by Dmitry Rabkin, MD, at Brigham and Women’s Hospital (BWH) in Boston, Massachusetts. At BWH, the clinical trial is led by Dr. Rabkin, who is Assistant Chief, Division of Angiography & Interventional Radiology.
The investigational, remotely operated Liberty system aims to improve the way surgical robotics are being used in endovascular procedures, by eliminating the need for large, cumbersome, and expensive capital equipment, while reducing radiation exposure and physician strain, stated the company.
Advertisement
Advertisement
